| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Leo Luznik | |
| Ephraim J. Fuchs | |||
| Paul V. O'Donnell | |||
| P2860 | cites work | Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants | Q29619458 |
| Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation | Q33765556 | ||
| Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice | Q68292417 | ||
| Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens. Is mixed chimerism really required in maintaining a skin allograft tolerance? | Q68408783 | ||
| Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma | Q69482387 | ||
| Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia | Q69910338 | ||
| Cyclophosphamide-induced immunologic tolerance to skin homografts | Q69951970 | ||
| Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach | Q71555525 | ||
| Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo | Q71860122 | ||
| Cyclophosphamide-induced tolerance in fully allogeneic heart transplantation in mice | Q72415020 | ||
| Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells | Q72488507 | ||
| Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts | Q72734485 | ||
| Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings | Q73368611 | ||
| DOSE-RESPONSE RELATIONSHIPS FOR AGENTS INHIBITING THE IMMUNE RESPONSE | Q76702890 | ||
| Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype | Q77437408 | ||
| Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation | Q77898016 | ||
| IMMUNOGENETIC CONSEQUENCES OF VASCULAR ANASTOMOSES BETWEEN BOVINE TWINS | Q80949985 | ||
| Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free sur | Q84730771 | ||
| A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing | Q84831048 | ||
| High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. | Q33806054 | ||
| High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation | Q33941128 | ||
| Loss of mismatched HLA in leukemia after stem-cell transplantation. | Q34018719 | ||
| Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation | Q34162461 | ||
| Actively acquired tolerance of foreign cells | Q34233179 | ||
| Engraftment syndrome following hematopoietic stem cell transplantation | Q34298239 | ||
| Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome | Q34388640 | ||
| Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts | Q35112222 | ||
| Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance | Q35237468 | ||
| Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens | Q36350179 | ||
| Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide | Q36355820 | ||
| Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen | Q36355970 | ||
| HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide | Q37078261 | ||
| Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma | Q37108595 | ||
| Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation | Q37142892 | ||
| Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism | Q37211290 | ||
| Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation | Q37414729 | ||
| An update on regulatory T cells in transplant tolerance and rejection. | Q37777645 | ||
| Tolerance: an overview and perspectives | Q37780677 | ||
| Haploidentical hematopoietic transplantation: current status and future perspectives | Q37932881 | ||
| Marrow transplantation from donors other than HLA-identical siblings | Q39278390 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Cyclophosphamide-induced immunological tolerance: an overview | Q41172578 | ||
| Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation | Q42007990 | ||
| Marrow transplantation from related donors other than HLA-identical siblings | Q43519981 | ||
| Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide | Q43806522 | ||
| Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs | Q43977140 | ||
| Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide | Q44097089 | ||
| Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients | Q44723585 | ||
| Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. | Q45309204 | ||
| Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation. | Q50872473 | ||
| Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation. | Q53302219 | ||
| A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers | Q54159225 | ||
| Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice | Q54471768 | ||
| Transplantation of anergic histoincompatible bone marrow allografts | Q56906962 | ||
| Drug-induced Immunological Tolerance | Q59059733 | ||
| Immunological Tolerance induced by Cyclophosphamide assayed by Plaque Spleen Cell Method | Q59074166 | ||
| Prolongation of Homograft Survival in Mice with Single Doses of Cyclophosphamide | Q59096652 | ||
| MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA | Q60497057 | ||
| Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. | Q64988288 | ||
| Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A | Q67907822 | ||
| Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion | Q67946159 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bone marrow | Q546523 |
| P304 | page(s) | 683-93 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Seminars in Oncology | Q14330412 |
| P1476 | title | Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation | |
| P478 | volume | 39 |
| Q98289229 | A phase I study of CAR-T bridging HSCT in patients with acute CD19+ relapse/refractory B-cell leukemia |
| Q52888768 | A pilot study of operational tolerance with a regulatory T-cell-based cell therapy in living donor liver transplantation. |
| Q95610652 | A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2 |
| Q45917057 | A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. |
| Q48074139 | Achieving immune tolerance in hand and face transplantation: a realistic prospect? |
| Q35586614 | Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation |
| Q28080943 | Alternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia |
| Q30252339 | Alternative Donor Graft Sources for Adults with Hematologic Malignancies: A Donor for All Patients in 2017! |
| Q38366520 | An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide |
| Q26776396 | An update of current treatments for adult acute myeloid leukemia |
| Q41185627 | Are alternative donors really still "alternative?". |
| Q94546330 | Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia |
| Q64953350 | Bone Marrow Transplantation 1957-2019. |
| Q95319163 | Brief ex vivo Fas-ligand incubation attenuates GvHD without compromising stem cell graft performance |
| Q64374661 | CTLA4Ig-based T-cell costimulation blockade is associated with reduction of adenovirus viremia following post-transplantation cyclophosphamide-based haploidentical transplantation |
| Q38750270 | Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation. |
| Q37618838 | Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide |
| Q38155240 | Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation |
| Q37505854 | Cyclophosphamide alters the gene expression profile in patients treated with high doses prior to stem cell transplantation. |
| Q96767827 | Cytokine release syndrome after allogeneic stem cell transplantation with post-transplant cyclophosphamide |
| Q26863564 | Desensitization for solid organ and hematopoietic stem cell transplantation |
| Q34293038 | Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice |
| Q89556730 | Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD |
| Q28082397 | FOXP3+ regulatory T cells and their functional regulation |
| Q86852075 | Familial haploidentical challenging unrelated donor Allo-SCT in advanced non-Hodgkin lymphomas when matched related donor is not available |
| Q39018591 | Foxp3, Regulatory T Cell, and Autoimmune Diseases |
| Q60301023 | HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment |
| Q51003191 | Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. |
| Q40296052 | Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide |
| Q38190856 | Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers |
| Q91695742 | Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Primary Immune Deficiency Disorders in Children: Challenges and Outcome from a Tertiary Care Center in South India |
| Q90583023 | Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update |
| Q50058671 | Haploidentical bone marrow transplantation with post transplant cyclophosphamide for patients with X-linked adrenoleukodystrophy: a suitable choice in an urgent situation |
| Q28080452 | Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives |
| Q40660339 | Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies |
| Q38248521 | Haploidentical stem cell transplantation for the treatment of leukemia: current status |
| Q39741420 | Haploidentical transplantation in children with unmanipulated peripheral blood stem cell graft: The need to look beyond post-transplantation cyclophosphamide in younger children. |
| Q52839289 | Haploidentical transplantation with post-transplant cyclophosphamide following reduced-intensity conditioning for osteopetrosis: outcomes in three children. |
| Q92710251 | Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT |
| Q41697458 | Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update |
| Q38252578 | Hematopoietic Cell Transplantation for Older Patients with MDS. |
| Q35924098 | Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. |
| Q90197717 | High prevalence of CD3, NK, and NKT cells in the graft predicts adverse outcome after matched-related and unrelated transplantations with post transplantation cyclophosphamide |
| Q41031184 | Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation |
| Q26748867 | How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? |
| Q99712088 | Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization |
| Q34477411 | Improving the safety of cell therapy with the TK-suicide gene |
| Q39425529 | In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review |
| Q41676842 | Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. |
| Q39176256 | Induction of Major Histocompatibility Complex-mismatched Mouse Lung Allograft Acceptance With Combined Donor Bone Marrow: Lung Transplant Using a 12-Hour Nonmyeloablative Conditioning Regimen |
| Q40140952 | Infusion-related febrile reaction after haploidentical stem cell transplantation in children is associated with higher rates of engraftment syndrome and acute graft-versus-host disease. |
| Q92071883 | Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding |
| Q28067102 | Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments |
| Q26797506 | Modern approaches to HLA-haploidentical blood or marrow transplantation |
| Q47194084 | Mucosal-Associated Invariant T Cells Display a Poor Reconstitution and Altered Phenotype after Allogeneic Hematopoietic Stem Cell Transplantation |
| Q34402494 | Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning |
| Q37197917 | Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation |
| Q47847626 | NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. |
| Q47570438 | NK cell therapy after hematopoietic stem cell transplantation: can we improve anti-tumor effect? |
| Q49566331 | NK cell therapy for hematologic malignancies |
| Q92519643 | Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy |
| Q92092785 | Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture) |
| Q26748780 | Nonmyeloablative allogeneic hematopoietic cell transplantation |
| Q36833808 | OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantation |
| Q36090971 | Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. |
| Q91844291 | PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade |
| Q37029856 | Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation |
| Q55240175 | Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. |
| Q92023496 | Post-transplant cyclophosphamide use in matched HLA donors: a review of literature and future application |
| Q89372230 | Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation |
| Q94561547 | Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation |
| Q92735540 | Post-transplantation cyclophosphamide for chimerism-based tolerance |
| Q64112565 | Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression |
| Q33764825 | Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation |
| Q36700499 | Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation |
| Q43450856 | Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. |
| Q89998053 | Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources |
| Q40715280 | Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. |
| Q51770643 | Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. |
| Q51278491 | Report From the First and Second Spanish Killer Immunoglobulin-Like Receptor Genotyping Workshops: External Quality Control for Natural Killer Alloreactive Donor Selection in Haploidentical Stem Cell Transplantation. |
| Q35584266 | Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. |
| Q95658212 | Second Allogeneic Hematopoietic Stem Cell Transplantation After Donor Replacement in Children With Severe Aplastic Anemia |
| Q87729517 | Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier |
| Q39673383 | Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated |
| Q42362685 | Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies |
| Q36445665 | Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies |
| Q34684038 | Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. |
| Q53837722 | Single-agent GvHD prophylaxis with tacrolimus after post-transplant high-dose cyclophosphamide is a valid option for haploidentical transplantation in adults with hematological malignancies. |
| Q35506220 | Situational aldehyde dehydrogenase expression by regulatory T cells may explain the contextual duality of cyclophosphamide as both a pro-inflammatory and tolerogenic agent |
| Q60938512 | Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease |
| Q43029183 | Successful HLA haploidentical myeloablative stem cell transplantation for aggressive hepatosplenic alpha/beta (αβ) T-cell lymphoma. |
| Q58599400 | Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models |
| Q37012701 | Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA |
| Q28076264 | The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease |
| Q90346271 | The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide |
| Q28072397 | The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era |
| Q33917175 | The biology of graft-versus-host disease: experimental systems instructing clinical practice |
| Q89245550 | The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation |
| Q38959130 | The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy |
| Q30240238 | Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens |
| Q38510475 | Umbilical cord blood donation: public or private? |
| Q54212475 | Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. |
| Q33742940 | Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. |
| Q50588099 | Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies |
| Q38187340 | Very early onset inflammatory bowel disease associated with aberrant trafficking of IL-10R1 and cure by T cell replete haploidentical bone marrow transplantation. |
| Q26823536 | Which donor or graft source should you choose for the strongest GVL? Is there really any difference |
| Q93060546 | Who is the best haploidentical donor for acquired severe aplastic anemia? Experience from a multicenter study |
Search more.